Business News • PR NewsWire • Regeneron and Sanofi Announce Presentation of Positive Data from Long-Term Pivotal Phase 3 CHRONOS Study of DUPIXENT® (dupilumab) in Moderate-to-Severe Atopic Dermatitis

Regeneron and Sanofi Announce Presentation of Positive Data from Long-Term Pivotal Phase 3 CHRONOS Study of DUPIXENT® (dupilumab) in Moderate-to-Severe Atopic Dermatitis

Regeneron and Sanofi Announce Presentation of Positive Data from Long-Term Pivotal Phase 3 CHRONOS Study of DUPIXENT® (dupilumab) in Moderate-to-Severe Atopic Dermatitis

TARRYTOWN, N.Y. and PARIS, March 4, 2017 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented detailed results from the one-year Phase 3 CHRONOS study, which showed that patients receiving the investigational drug DUPIXENT with topical...

View More : http://www.prnewswire.com/news-releases/regeneron-and-sanofi-announce-presentation-of-positive-data-from-long-term-pivot...

Releted News by prnewswire

Madvapes Registers Products With Europe TPD!

New Head-to-Head Data Shows Significantly Higher Response Rates for Lilly's Taltz® (ixekizumab) Compared to Stelara® (ustekinumab) in Patients with Moderate-to-Severe Plaque Psoriasis

Performance de conscientização "A Better High" da HEAVENSAKE na Catedral Americana em Paris

Fintech Business, Beehive, is the First Peer to Peer Lending Platform to Receive DFSA Regulation